GLP-1 Comparison · 2026
Compounded Semaglutide vs Ozempic
Same active molecule, different supply chain, dramatically different cost. This is the honest 2026 breakdown of what differs between compounded semaglutide prepared at a 503A pharmacy and brand-name Ozempic — and what doesn't differ at all.
Published 30 May 2026 · 14-minute read
Quick Answer
Compounded semaglutide and Ozempic contain the same active ingredient (semaglutide) but are produced through different supply chains. Compounded semaglutide is prepared at a 503A pharmacy with a B-12 or glycine carrier, costs roughly $199–279/month at RxPepsDirect versus ~$1,400/month for Ozempic list price, and is not FDA-approved as a drug product. The pharmacological mechanism is identical at equivalent doses.
1. Is compounded semaglutide the same as Ozempic? (the molecule answer)
Ozempic (semaglutide injection) is a GLP-1 receptor agonist approved by the FDA in 2017 for type 2 diabetes management and subsequently used off-label — and as Wegovy — for weight loss. The active ingredient is a 34-amino acid GLP-1 analog with a C-18 fatty diacid chain that extends its half-life to approximately one week.
Compounded semaglutide uses the same active pharmaceutical ingredient (API): semaglutide. A 503A compounding pharmacy sources USP-grade semaglutide, verifies identity and potency via certificate of analysis, and prepares a sterile injectable solution in a patient-specific vial. The molecule that leaves the compounding pharmacy is chemically the same molecule that leaves Novo Nordisk's factory.
The differences are in: (1) the excipients and carrier — Ozempic uses disodium phosphate dihydrate, propylene glycol, and phenol; compounded versions typically use cyanocobalamin (B-12) or glycine/B-6 as a carrier; (2) the regulatory pathway — Ozempic holds an NDA, compounded semaglutide does not; (3) the concentration and delivery format — Ozempic comes as a pre-filled pen, compounded as a multi-dose vial; and (4) cost.
What is the same: the active molecule, its GLP-1 receptor agonist mechanism, its pharmacokinetic profile at equivalent doses, and the expected clinical effect.
2. Why compounded semaglutide exists (the 503A pathway)
Section 503A of the Federal Food, Drug, and Cosmetic Act permits licensed pharmacies to compound prescription medications for individual patients without obtaining FDA new-drug approval. The exemption exists because no single approved product can meet every patient's clinical need — allergy to an excipient, a dose not available in a commercial form, or access barriers to brand-name products.
During 2022–2024, Ozempic and Wegovy faced significant supply shortages. The FDA placed semaglutide on its drug shortage list, which explicitly permitted 503A pharmacies to compound semaglutide for individual patients. The shortage designation has since been updated, but patient-specific compounding under 503A remains a legal pathway as long as the compounding meets USP <797> sterile requirements and the pharmacy holds appropriate state licensure.
RxPepsDirect prescriptions are filled by Optimal Balance Pharmacy (OBP), a licensed 503A compounding pharmacy. Every batch undergoes sterility testing per USP <71>, endotoxin testing per USP <85>, and potency verification before dispensing.
For a detailed explainer on how 503A pharmacies work and what regulations they operate under, see What Is a 503A Pharmacy?
3. Active ingredient comparison: identical or different?
The semaglutide API in compounded formulations is the same molecule as in Ozempic. Here's how quality is verified in the 503A supply chain:
Same API source, USP-grade, certificate of analysis
OBP sources semaglutide API that meets USP monograph specifications. Each lot comes with a certificate of analysis (COA) confirming: identity (HPLC/MS), purity (≥98%), residual solvents, and heavy metal limits. The COA is the bridge between the API supplier's quality assurance and the compounding pharmacy's release testing.
Finished vials undergo independent batch testing: sterility (ScanRDI method, USP <71>), endotoxin (<0.5 EU/mL, USP <85>), and potency (HPLC, USP <621>). A vial that fails any parameter is not dispensed.
The key difference from Ozempic is not in the API but in the excipient profile. Ozempic's commercial formulation uses a proprietary buffered vehicle. Compounded semaglutide uses cyanocobalamin (B-12) as the default carrier at OBP — or glycine/B-6 for patients who are B-12-sensitive, have MTHFR variants, or have histamine reactivity. The carrier is pharmacologically inert with respect to GLP-1 receptor agonism.
For the full carrier comparison, see Glycine vs B-12 carrier: which compounded GLP-1 formulation fits which patient.
4. Cost comparison: brand vs compounded, with insurance and without
| Factor | Ozempic (brand) | Compounded Semaglutide (RxPepsDirect) |
|---|---|---|
| List price | ~$1,400/mo | From $25/vial (pass-through wholesale) |
| With commercial insurance | $0–$25 copay if covered for T2D; rarely covered for weight loss | Not covered by insurance; OOP only |
| Without insurance (cash pay) | ~$900–$1,400/mo with GoodRx | ~$199–$279/mo at typical titration |
| Telehealth visit fee | Varies by prescriber | $39 one-time consult at RxPepsDirect |
| Delivery | Pharmacy pickup or mail-order | FedEx overnight from OBP |
| FDA approval status | FDA-approved NDA | Not FDA-approved; 503A compounded |
| Active ingredient | Semaglutide | Semaglutide (same molecule) |
| Carrier/excipient | Proprietary buffered vehicle | B-12 (default) or glycine/B-6 |
| Batch testing | Manufacturer QC (not published per-lot) | Per-lot COA: sterility, endotoxin, potency |
The cost gap is structural, not a sign of inferior quality. Ozempic's list price reflects Novo Nordisk's decade-long clinical development program, FDA approval costs, manufacturing at commercial scale, and the distribution chain from manufacturer to wholesaler to pharmacy to patient. Compounded semaglutide skips every one of those layers.
For patients with commercial insurance covering Ozempic for type 2 diabetes, the brand copay can be lower than the out-of-pocket cost of compounded semaglutide. For everyone else — the cash-pay majority using GLP-1s for weight loss — the cost difference is roughly 5–7× in favor of compounded.
5. Dosing equivalence and titration
Ozempic's labeled dose schedule for T2D starts at 0.5 mg/week, escalates to 1 mg/week, and has a 2 mg/week option. Wegovy (higher-dose semaglutide for obesity) runs a longer escalation to 2.4 mg/week. Both are delivered as weekly injections via pre-filled pen.
RxPepsDirect's compounded semaglutide/B12 starts at a 1.2 mg vial (0.6 mg/mL × 2 mL). The default starting protocol is 25 units (0.15 mg) injected twice weekly = approximately 0.3 mg/week — a conservative starting point that allows the body to acclimate before escalating. Titration vials are available from 2.4 mg up to 30 mg, and the full dose ladder covers weekly equivalent doses from 0.3 mg/week up to and beyond Wegovy's 2.4 mg/week ceiling.
Twice-weekly subcutaneous injection is equivalent in total weekly dose to a once-weekly injection at the same total. The split-dose approach can reduce peak-concentration side effects (nausea, GI distress) common in the first few weeks of GLP-1 therapy.
If you are switching from Ozempic, your current weekly dose in mg is the reference point. A provider will select the compounded vial concentration that allows you to draw an equivalent dose and continue your established titration step.
6. Safety profile: the FDA position, the clinical evidence
The safety profile of semaglutide is well established from Novo Nordisk's clinical program: SUSTAIN (T2D), STEP (obesity), and SURMOUNT-adjacent comparisons. The most common adverse effects are GI — nausea, vomiting, diarrhea, constipation — dose-dependent and typically resolving within the first 4–8 weeks of a given dose. The labeled class warnings (medullary thyroid carcinoma risk, pancreatitis, gastroparesis) apply to any form of semaglutide regardless of origin.
The FDA has issued warnings about compounded GLP-1 products, focused on two concerns: (1) formulations containing semaglutide sodium or semaglutide acetaterather than the base form used in approved drugs, and (2) quality-control failures at lower-tier compounders. Neither concern applies to a licensed 503A pharmacy using verified USP-grade semaglutide base and publishing per-lot batch testing results.
There is no head-to-head randomized trial comparing compounded semaglutide to Ozempic. Given that the active molecule is identical at equivalent doses, the mechanistic expectation is the same efficacy and safety profile. The honest caveat is that “expected to be equivalent” is not the same as “proven equivalent in a trial.” Patients who require the regulatory certainty of an FDA-approved product should use Ozempic or Wegovy.
Standard GLP-1 contraindications apply to both: personal or family history of medullary thyroid carcinoma or MEN2, active pancreatitis, severe gastroparesis, pregnancy, or current insulin use (flag for provider review).
7. When compounded semaglutide makes sense, when Ozempic makes sense
Compounded semaglutide makes sense when:
- ✓You are a cash-pay patient without insurance coverage for branded GLP-1s
- ✓Your insurance covers Ozempic only for T2D but you need it for weight loss
- ✓You want flexible dose titration (vials, not fixed-pen steps)
- ✓You have a B-12 sensitivity and need a glycine/B-6 carrier option
- ✓You want microdose access below Ozempic's 0.5 mg starting step
- ✓You are switching from Ozempic and want to maintain the same dose at lower cost
Ozempic makes sense when:
- →Your insurance covers it and your copay is below the compounded cost
- →You require the regulatory certainty of an FDA-approved product
- →Your provider specifically prescribes the branded pen for clinical reasons
- →You prefer the convenience of a pre-filled, dose-dialed pen
- →You are being treated for T2D under a diabetes management protocol tied to the branded label
8. RxPepsDirect compounded semaglutide formulation (B-12 carrier default)
RxPepsDirect prescriptions are filled exclusively by Optimal Balance Pharmacy (OBP, practice ID 1042913), a licensed 503A sterile compounding pharmacy. The default compounded semaglutide formulation is Semaglutide/B12: semaglutide API with cyanocobalamin as the carrier excipient.
Dose ladder (OBP wholesale, no markup)
Starting vial: 0.6 mg/mL × 2 mL = 1.2 mg total. Standard starting dose: 25 units (0.15 mg) twice weekly. BUD: up to 120 days from compounding (USP <797>).
The Semaglutide/B6 + Glycine formulation is available for patients with confirmed or suspected B-12 sensitivity, MTHFR variants affecting methylation, or histamine reactivity. It uses the same semaglutide API and the same GLP-1 mechanism; the carrier is the only change. The glycine formulation is dispensed in 10 mg ($175) and 30 mg ($425) vials.
Both formulations are shipped FedEx overnight from OBP. The $39 RxPepsDirect consult fee covers provider review, prescription, and ongoing titration support. See full pricing or browse the Weight Loss & Metabolic catalog.
9. How to get a prescription for compounded semaglutide
The prescription pathway at RxPepsDirect is a single asynchronous telehealth consult:
- Complete the intake form — medical history, current medications, contraindication screening (thyroid cancer history, MEN2, pancreatitis, gastroparesis, pregnancy).
- Pay the $39 visit fee — this covers provider review and prescription issuance. There is no recurring subscription; you pay $39 per visit cycle.
- Provider reviews your intake — a licensed provider in your state reviews your intake asynchronously and, if clinically appropriate, issues a prescription to OBP.
- OBP compounds and ships — your vial is compounded to order under USP <797>, batch-tested, and shipped FedEx overnight. Typical turnaround is 2–4 business days from consult approval.
- Titrate with provider support — follow-up intake forms allow you to request dose escalation vials as you progress through the titration ladder.
RxPepsDirect is licensed in 28 states and the District of Columbia as of May 2026. Check your eligibility before starting the intake.
For more context on how compounded semaglutide compares to other telehealth providers, see Best compounded semaglutide telehealth in 2026. For the semaglutide vs tirzepatide question, see Semaglutide vs tirzepatide for weight loss.
Frequently Asked Questions
Is compounded semaglutide the same as Ozempic?
They contain the same active ingredient — semaglutide — but are produced through different supply chains. Ozempic is FDA-approved and manufactured by Novo Nordisk. Compounded semaglutide is prepared patient-specifically at a licensed 503A pharmacy using USP-grade semaglutide API. The molecule is identical; the regulatory pathway and carrier excipients differ.
Why is compounded semaglutide cheaper than Ozempic?
Ozempic's list price (~$1,400/month) includes FDA approval costs, large-scale manufacturing, marketing, and distribution margins. Compounded semaglutide bypasses all of those layers: a 503A pharmacy sources pharmaceutical-grade API and ships directly through a telehealth prescriber. RxPepsDirect passes through OBP's wholesale cost with no markup, starting at $25 per vial.
Is compounded semaglutide FDA-approved?
No. Compounded semaglutide is not FDA-approved as a drug product. It is prepared under Section 503A of the FDCA, which exempts patient-specific compounded medications from the FDA's new-drug approval requirements. The pharmacy is regulated by state boards of pharmacy and must meet USP <797> sterile compounding standards.
Does compounded semaglutide work as well as Ozempic?
No head-to-head trial directly compares the two. Because the active ingredient is the same molecule at equivalent doses, the pharmacological mechanism is expected to be identical. Clinical outcomes depend on dose, adherence, diet, and individual response — the same variables regardless of whether semaglutide came from a branded pen or a compounded vial.
What is the B-12 in compounded semaglutide?
Cyanocobalamin (vitamin B-12) serves as a carrier excipient in the default OBP formulation. It is pharmacologically inert with respect to the GLP-1 mechanism. The B-12 supports energy levels during caloric restriction. Patients with B-12 sensitivity can request the glycine/B-6 formulation instead.
Can I switch from Ozempic to compounded semaglutide?
Yes. Because the active ingredient is semaglutide in both cases, your current Ozempic dose provides a titration baseline your prescriber can use to select an equivalent compounded vial concentration. The switch should be supervised by a licensed provider.
Is compounded semaglutide still legal in 2026?
Yes. Patient-specific compounding under Section 503A remains a lawful pathway as of 2026 as long as the pharmacy holds appropriate state licensure and compounds under USP <797> standards. Compounding for individual patients with a valid prescription is distinct from the broader shortage-period rules that have since been updated.
How is compounded semaglutide dosed?
RxPepsDirect's starter vial is 1.2 mg total (0.6 mg/mL × 2 mL). The default starting dose is 25 units (0.15 mg) twice weekly ≈ 0.3 mg/week. Titration vials from 2.4 mg up to 30 mg allow a dose ladder that matches or exceeds Ozempic's and Wegovy's on-label schedules.
Related reading
- Semaglutide vs tirzepatide for weight loss: which one wins in 2026
- Compounded tirzepatide vs Mounjaro vs Zepbound: a 2026 comparison
- Glycine vs B-12 carrier: which compounded GLP-1 formulation fits which patient
- What Is a 503A Pharmacy? The 2026 Guide to Compounded Medication Safety
- Best compounded semaglutide telehealth in 2026
Ready to get started?
Get compounded semaglutide from $25/vial
$39 telehealth consult · Provider-reviewed · OBP batch-tested · FedEx overnight
Start my consult →This article is for informational purposes only and does not constitute medical advice. Compounded semaglutide is not FDA-approved. Consult a licensed healthcare provider before starting, changing, or stopping any medication. RxPepsDirect prescriptions are filled by Optimal Balance Pharmacy, a licensed 503A compounding pharmacy.